Genmont Biotech Overview
- Founded
-
2000

- Status
-
Public
- Employees
-
147

- Stock Symbol
-
3164

- Share Price
-
$0.85
- (As of Wednesday Closing)
Genmont Biotech General Information
Description
GenMont Biotech Inc is engaged in the research, development, manufacturing and selling of a variety of probiotic supplements.
Contact Information
Primary Industry
Pharmaceuticals
Stock Exchange
TAI
Primary Office
- No.8, Tainan Science-Based Industrl Prk Nan-Ke
- 7th Road Shanhua District
- Shanhua, 741
- Taiwan
+886 06 000 0000
Genmont Biotech Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.85 | $0.84 | $0.65 - $0.98 | $73.1M | 86.4M | 104K | $0.02 |
Genmont Biotech Financials Summary
In Thousands, USD |
TTM 31-Mar-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
---|---|---|---|---|
EV | 62,496 | 59,432 | 69,975 | 59,586 |
Revenue | 11,762 | 12,379 | 15,313 | 11,048 |
EBITDA | 3,169 | 3,783 | 5,701 | 3,278 |
Net Income | 1,380 | 1,914 | 4,048 | 2,068 |
Total Assets | 55,844 | 55,278 | 61,326 | 57,822 |
Total Debt | 1,133 | 1,126 | 1,182 | 1,231 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Genmont Biotech Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Genmont Biotech Patents
Genmont Biotech Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20230081322-A1 | Lactobacillus composition and use thereof for improving anxiety caused by antibiotics | Pending | 06-Sep-2021 | 000000000 | 0 |
US-20220031775-A1 | Probiotic composition and method for improving an effect of chemotherapeutic drug of gemcitabine on inhibiting pancreatic cancer | Pending | 29-Jul-2020 | 0000000000 | 0 |
US-20210213076-A1 | Lactobacillus paracasei gmnl-346 for anti-oral cancer treatment and thereof | Pending | 14-Jan-2020 | 0000000000 | |
US-10639336-B1 | Use of a probiotic composition for preventing stroke and ameliorating the severity of stroke | Active | 10-Jun-2019 | 0000000000 | |
US-20200077692-A1 | Lactobacillus composition for inhibiting gastritis induced by gastric helicobacter pylori and use thereof | Active | 12-Sep-2018 | A61P1/04 |